טוען...

Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL

Chronic lymphocytic leukemia (CLL) patients progressed early on ibrutinib often develop Richter transformation (RT) with a short survival of about 4 months. Preclinical studies suggest that programmed death 1 (PD-1) pathway is critical to inhibit immune surveillance in CLL. This phase 2 study was de...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
הוצא לאור ב:Blood
Main Authors: Ding, Wei, LaPlant, Betsy R., Call, Timothy G., Parikh, Sameer A., Leis, Jose F., He, Rong, Shanafelt, Tait D., Sinha, Sutapa, Le-Rademacher, Jennifer, Feldman, Andrew L., Habermann, Thomas M., Witzig, Thomas E., Wiseman, Gregory A., Lin, Yi, Asmus, Erik, Nowakowski, Grzegorz S., Conte, Michael J., Bowen, Deborah A., Aitken, Casey N., Van Dyke, Daniel L., Greipp, Patricia T., Liu, Xin, Wu, Xiaosheng, Zhang, Henan, Secreto, Charla R., Tian, Shulan, Braggio, Esteban, Wellik, Linda E., Micallef, Ivana, Viswanatha, David S., Yan, Huihuang, Chanan-Khan, Asher A., Kay, Neil E., Dong, Haidong, Ansell, Stephen M.
פורמט: Artigo
שפה:Inglês
יצא לאור: American Society of Hematology 2017
נושאים:
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC5492091/
https://ncbi.nlm.nih.gov/pubmed/28424162
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2017-02-765685
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!